iberdomide
Selected indexed studies
- EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. (Future Oncol, 2025) [PMID:40346992]
- Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus. (N Engl J Med, 2022) [PMID:35294813]
- Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma. (Clin Lymphoma Myeloma Leuk, 2024) [PMID:39003099]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. (2025) pubmed
- Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus. (2022) pubmed
- Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma. (2024) pubmed
- Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide. (2024) pubmed
- Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse. (2025) pubmed
- Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study. (2022) pubmed
- [Iberdomide against Aiolos and Ikaros in systemic lupus erythematosus]. (2022) pubmed
- Iberdomide with dexamethasone: a new backbone for myeloma treatment? (2022) pubmed
- Exposure-Response Analysis to Assess the Concentration-QTc Relationship of Iberdomide. (2023) pubmed
- Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma. (2024) pubmed